Article
Watson Pharmaceuticals Inc. and Debiopharm S.A. have agreed to market triptorelin pamoate (Trelstar Depot, 3.75 mg, and Trelstar LA, 11.25 mg) within the United States and Canada.
Pivotal data for lumasiran in PH1 published in NEJM
Nedosiran explored in primary hyperoxaluria type 3
Enrollment completed in pivotal trial of nedosiran for hyperoxaluria
FDA approves androgen inhibitor for metastatic PCa
Blood test could guide treatment for kidney cancer
BCG for bladder cancer in short supply
FDA approves mitomycin intravesical solution for recurrent LG-IR-NMIBC
AI-based tool aims to optimize MRI use in prostate cancer diagnosis
PSMA-PET imaging product, Gozellix, launches on US market
Adding cetrelimab to niraparib maintenance shows benefit in aggressive variant prostate cancer